Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: Implications for the pathogenesis of the on-off phenomenon

Journal of Neurology Neurosurgery and Psychiatry

Volumn 60, Issue 6, 1996, Pages 634-637

  Colosimo, Carlo ^a   Merello, Marcelo ^a   Hughes, Andrew J ^a   Sieradzan, Katarzyna ^a   Lees, Andrew J ^a,b  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

Apomorphine; Levodopa; On off effect; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; APOMORPHINE; LEVODOPA;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; LATENT PERIOD; MALE; MOTOR ACTIVITY; ON OFF PHENOMENON; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROVOCATION TEST; REGRESSION ANALYSIS;

EID: 0029920096     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.60.6.634     Document Type: Article

References (27)

1. Fahn S. "On-off" phenomenon with levodopa therapy in parkinsonism. Clinical and pharmacologic correlations and the effects of intramuscular pyridoxine. Neurology 1974;24:431-41.
2. Gancher ST, Nutt JG, Woodward WR. Peripheral pharmacokinetics of L-dopa in untreated, stable, and fluctuating Parkinsonian patients. Neurology 1987;37:940-44.
3. Fabbrini G, Mouradian M, Juncos JL, Schlegel J, Mohr E, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanism, part I. Ann Neurol 1988;24:366-71.
4. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Barkto JJ, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanism, part II. Ann Neurol 1988;24:372-8.
5. Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 1994;36:27-31.
6. Gancher ST, Nutt JG, Woodward WR. Response to brief levodopa infusions in Parkinsonian patients with and without motor fluctuations. Neurology 1988;38:712-6.
7. Nutt JG, Woodward WR, Carter JH, Gancher ST. Effect of long-term therapy on the pharmacodynamics of L-dopa. Relation to on-off phenomenon. Arch Neurol 1992;49: 1123-30.
8. Contin M, Riva R, Martinelli P, et al. Response to standard oral L-dopa test in parkinsonian patients with and without motor fluctuations. Clin Neuropharmacol 1990;13:19-28.
9. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
10. Webster DD. Critical analysis of the disability in Parkinson's disease. Mod Treat 1968;5:257-82.
11. Hughes AJ, Lees AJ, Stern GM. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet 1990:ii:32-4.
12. Colosimo C, Merello M, Albanese A. Clinical usefulness of apomorphine in movement disorders. Clin Neuropharmacol 1994;17:243-59.
13. Kempster PA, Gibb WRG, Lees AJ, Stern GM. Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of motor fluctuations. J Neurol Neurosurg Psychiatry 1989; 52:72-6.
14. Kempster PA, Frankel JP, Bovingdon M, Webster R, Lees AJ, Stern GM. Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease. J Neurol Neurosurg Psychiatry 1989;52:718-23.
15. Grandas F, Gancher ST, Rodriguez M, Lera G, Nutt JG, Obeso JA. Differences in the motor response to apomorphine between untreated and fluctuating patients with Parkinson's disease. Clin Neuropharmacol 1992;15:13-8.
16. Rodriguez M, Lera G, Vaamonde J, Luquin MR, Obeso JA. Motor response to apomorphine in asymmetric Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57:562-6.
17. 18F] fluoroethylspiperone: findings in disorders related to dopaminergic system. J Neural Transm 1990;81:195-213.
18. Leenders KL, Herold S, Palmer AJ, et al. Human cerebral dopamine system measured in vivo using PET. J Cereb Blood Flow Metabol 1985;5:S157-8.
19. Rinne UK, Lonnberg P, Koskinen V. Dopamine receptors in the Parkinsonian brain. J Neural Transm 1981;51: 97-106.
20. Sohn YH, Verhagen Metman L, et al. Levodopa peak response time reflects severity of dopamine neuron loss in Parkinson's disease. Neurology 1994;44:755-7.
21. Melamed E, Billon V, Zelig O. Delayed onset of responses to single doses of L-DOPA in parkinsonian fluctuators on long-term L-DOPA therapy. Clin Neuropharmacol 1986; 9:182-8.
22. Muenter MD, Tyce GM. L-DOPA therapy of Parkinson's disease: plasma L-DOPA concentration, therapeutic response, and side-effects. Mayo Clin Proc 1971;46: 231-9.
23. Hughes AJ, Frankel JP, Kempster PA, Frankel JP, Stern GM, Lees AJ. Motor response to levodopa in patients with parkinsonian motor fluctuations: a follow-up study over three years. J Neurol Neurosurg Psychiatry 1994;57: 430-4.
24. Langston JW, Ballard PA. Parkinsonism induced by 1-methyl-4-phenyl, 1,2,3,6, tetrahydropyridine (MPTP): implications for treatment and pathogenesis of Parkinson's disease. Can J Neurol Sci 1984;11:160-5.
25. Duvoisin RC, Lobo-Antunes J, Yahr MD. Response of patients with postencephalitic parkinsonism to levodopa. J Neurol Neurosurg Psychiatry 1972;35:487-95.
26. Mouradian MM, Heuser JD, Baronti F, Chase TN. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 1990;27:18-23.
27. Vaamonde J, Luquin MR, Obeso JA. Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease. Mov Disord 1990;5:260-2.